NBIX
What one share of Neurocrine Biosciences holds
Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders.
Neurocrine Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $32.60 |
|---|---|
| Profit | $6.82 |
| Capex (buildings and equipment) | $0.27 |
| Free cash flow | $8.41 |
| Cash and investments | $3.27 |
| Book value | $36.35 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.17 | −$1.63 | $0.05 | −$1.27 | — | $3.62 |
| 2017 | $1.83 | −$1.62 | $0.08 | −$1.15 | — | $4.19 |
| 2018 | $4.73 | $0.22 | $0.26 | $0.80 | — | $5.30 |
| 2019 | $8.24 | $0.39 | $0.15 | $1.38 | — | $6.90 |
| 2020 | $10.69 | $4.16 | $0.11 | $2.22 | — | $12.04 |
| 2021 | $11.58 | $0.92 | $0.24 | $2.38 | — | $14.48 |
| 2022 | $15.05 | $1.56 | $0.17 | $3.26 | — | $17.70 |
| 2023 | $18.68 | $2.47 | $0.28 | $3.58 | — | $22.61 |
| 2024 | $22.71 | $3.29 | $0.37 | $5.37 | — | $26.05 |
| 2025 | $27.91 | $4.67 | $0.33 | $7.30 | — | $32.50 |